Study on data management and diagnosis-treatment mode of TCM intervention for novel coronavirus pneumonia (COVID-19) convalescence

注册号:

Registration number:

ITMCTR2000003257

最近更新日期:

Date of Last Refreshed on:

2020-04-29

注册时间:

Date of Registration:

2020-04-29

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

新型冠状病毒肺炎(COVID-19)恢复期中医药干预的数据管理与诊疗模式研究

Public title:

Study on data management and diagnosis-treatment mode of TCM intervention for novel coronavirus pneumonia (COVID-19) convalescence

注册题目简写:

English Acronym:

研究课题的正式科学名称:

新型冠状病毒肺炎(COVID-19)恢复期中医药干预的数据管理与诊疗模式研究

Scientific title:

Study on data management and diagnosis-treatment mode of TCM intervention for novel coronavirus pneumonia (COVID-19) convalescence

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

2020YFC0845000

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2000032480 ; ChiMCTR2000003257

申请注册联系人:

刘佳

研究负责人:

刘保延

Applicant:

Liu Jia

Study leader:

Liu Baoyan

申请注册联系人电话:

Applicant telephone:

+86 18810877011

研究负责人电话:

Study leader's telephone:

+86 010-64089669

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

marie_liujia@sina.cn

研究负责人电子邮件:

Study leader's E-mail:

liuby5505@139.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

北京市东城区东直门内南小街16号

研究负责人通讯地址:

北京市东城区东直门内南小街16号

Applicant address:

16 Nan-Xiao-Jie Street, Dong-Zhi-Men-Nei, Dongcheng District, Beijing, China

Study leader's address:

16 Nan-Xiao-Jie Street, Dong-Zhi-Men-Nei, Dongcheng District, Beijing, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中国中医科学院中医临床基础医学研究所

Applicant's institution:

Institute of Basic Research for Clinical Medicine, China Academy of Chinese Medical Sciences

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

HBZY2020-C25-01

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

湖北省中医院伦理委员会

Name of the ethic committee:

Ethic Committee of Hubei TCM Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2020/4/20 0:00:00

伦理委员会联系人:

张馨

Contact Name of the ethic committee:

Zhang Xin

伦理委员会联系地址:

湖北省武汉市武昌区花园山4号

Contact Address of the ethic committee:

4 Huayuan Hill, Wuchang District, Wuhan, Hubei, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 027-88920956

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中国中医科学院中医药信息研究所,中国中医科学院中医药数据中心

Primary sponsor:

TCM Data Center, CACMS; Institute of Information on Traditional Chinese Medicine, CACMS

研究实施负责(组长)单位地址:

北京市东城区东直门内南小街16号

Primary sponsor's address:

16 Nan-Xiao-Jie Street, Dong-Zhi-Men-Nei, Dongcheng District, Beijing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

中华人民共和国科技部

具体地址:

北京市复兴路乙15号

Institution
hospital:

Ministry of Science and Technology of People's Republic of China

Address:

B-15 Fuxing Road

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

中国中医科学院中医药信息研究所,中国中医科学院中医药数据中心

具体地址:

北京市东城区东直门内南小街16号

Institution
hospital:

TCM Data Center, CACMS; Institute of Information on Traditional Chinese Medicine, CACMS

Address:

16 Nan-Xiao-Jie Street, Dong-Zhi-Men-Nei, Dongcheng District

经费或物资来源:

国家重点研发计划“公共安全风险防控与应急技术装备”重点专项“新冠肺炎恢复期中医药干预的临床评价研究

Source(s) of funding:

National Key Research Plan Public security risk prevention control and emergency technical equipment, Key Project-Clinical Evaluation Study on TCM intervention for COVID-19

研究疾病:

新型冠状病毒肺炎(COVID-19)

研究疾病代码:

Target disease:

Novel Coronavirus Pneumonia (COVID-19)

Target disease code:

研究类型:

Study type:

观察性研究

Observational study

研究设计:

Study design:

连续入组

Sequential

研究所处阶段:

Study phase:

其它

Others

研究目的:

为新冠肺炎患者恢复期中医药干预效果评研究,搭建网络管理的数据平台;建立新冠肺炎恢复期患者社区管理新方法,搭建社区真实世界研究数据平台,提高新冠肺炎恢复期中医药的社区服务能力,形成社区病情诊疗及随访的服务规范及社区随访新模式。

Objectives of Study:

To evaluate the effect of TCM intervention for COVID-19 convalescence, build the internet management data platform; establish a new community patient management method of COVID-19 convalescence, build a community real world research data platform; to hence the community service capability of TCM for COVID-19 convalescence and finalize a service regulation and community follow-up new mode for diagnosis,treatment and follow-up.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1.确诊的新冠肺炎患者,进入恢复期; 2.解除隔离,居家康复; 3.签署知情同意书,愿意接受社区同意管理

Inclusion criteria

1. COVID-19 patient in convalescence stage; 2. Isolation removed and home rehabilitation; 3. Have signed the informed consent and agreed to be managed by community.

排除标准:

1.符合纳入标准,但正在参加其他科研课题者; 2.本人拒绝社区随访者;

Exclusion criteria:

1. Meeting the inclusion criteria but attending other studies; 2. Refusing to join the follow-up by community.

研究实施时间:

Study execute time:

From 2020-04-29

To      2021-04-22

征募观察对象时间:

Recruiting time:

From 2020-04-29

To      2021-04-22

干预措施:

Interventions:

组别:

观察组

样本量:

1000

Group:

Case series

Sample size:

干预措施:

实际干预措施

干预措施代码:

Intervention:

Practical Intervention

Intervention code:

样本总量 Total sample size : 1000

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

中国中医科学院中医药信息研究所,中国中医科学院中医药数据中心

单位级别:

Institution/hospital:

TCM Data Center, CACMS; Institute of Information on Traditional Chinese Medicine, CACMS

Level of the institution:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

中国中医科学院中医临床基础医学研究所

单位级别:

Institution/hospital:

Institute of Basic Research for Clinical Medicine, China Academy of Chinese Medical Sciences

Level of the institution:

国家:

中国

省(直辖市):

湖北

市(区县):

武汉

Country:

China

Province:

Hubei

City:

Wuhan

单位(医院):

湖北省中医院

单位级别:

三甲医院

Institution/hospital:

Hubei TCM Hospital

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

山东

市(区县):

济南

Country:

China

Province:

Shandong

City:

Jinan

单位(医院):

山东中医药大学

单位级别:

大学

Institution/hospital:

Shandong University of TCM

Level of the institution:

University

国家:

中国

省(直辖市):

湖北

市(区县):

孝感

Country:

China

Province:

Hubei

City:

Xiaogan

单位(医院):

湖北省孝感中医院

单位级别:

三甲医院

Institution/hospital:

Xiaogan TCM Hospital

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

辽宁

市(区县):

大连

Country:

China

Province:

Liaoning

City:

Dalian

单位(医院):

大连医谷科技有限公司

单位级别:

Institution/hospital:

Dalian Yigu Science and Technology Ltd

Level of the institution:

测量指标:

Outcomes:

指标中文名:

患者用药记录

指标类型:

主要指标

Outcome:

Record of Medication

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

症状量表

指标类型:

主要指标

Outcome:

syndrome scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

社区服务满意度评估

指标类型:

次要指标

Outcome:

Community service satisfaction assessment

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

患者病情记录

指标类型:

主要指标

Outcome:

Record of Disease

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小
Min age years
最大
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

盲法:

N/A

Blinding:

N/A

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

中国中医科学院院临床评价中心EDC系统

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

EDC system of Clinical Evaluation Center, China Academy of Chinese Medical Sciences

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

采用渔歌医疗平台APP采集信息,使用中国中医科学院临床评价中心EDC系统进行数据管理

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Use Yuge Medical Platform APP to collect data. Use EDC system of Clinical Evaluation Center, China Academy of Chinese Medical Sciences to achieve the data management.

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above